Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dare Bioscience (DARE) Cash from Operations (2016 - 2025)

Dare Bioscience (DARE) has disclosed Cash from Operations for 11 consecutive years, with 442135.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash from Operations rose 92.54% year-over-year to 442135.0, compared with a TTM value of 6097771.0 through Sep 2025, up 23.89%, and an annual FY2024 reading of 5400000.0, up 113.9% over the prior year.
  • Cash from Operations was 442135.0 for Q3 2025 at Dare Bioscience, up from 5417456.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 12904685.0 in Q2 2024 and bottomed at 16117571.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 4823118.63, with a median of 6586347.0 recorded in 2023.
  • The sharpest move saw Cash from Operations skyrocketed 551.37% in 2022, then plummeted 192.72% in 2023.
  • Year by year, Cash from Operations stood at 9915899.0 in 2021, then skyrocketed by 40.53% to 5896672.0 in 2022, then crashed by 38.7% to 8178905.0 in 2023, then surged by 163.97% to 5232363.0 in 2024, then tumbled by 108.45% to 442135.0 in 2025.
  • Business Quant data shows Cash from Operations for DARE at 442135.0 in Q3 2025, 5417456.0 in Q2 2025, and 5470543.0 in Q1 2025.